An observational study in Febrile Neutropenia, Rule of Clinical Decision, Chemotherapy, sponsored by University Hospital, Lille. Completed at 1 site in France. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by University Hospital, Lille · Observational
Among 16 studies in Febrile Neutropenia with a site in France — 1 open to participants now, 1 under way, 1 of them phase 3. Febrile Neutropenia · France.
Among the 16 studies in Febrile Neutropenia with a site in France, this one has the largest enrollment of the 10 observational ones that give a count, is the only one that started in 2012, is one of 10 observational ones, and was the 10th registered.
147 studies on the registry are indexed under Febrile Neutropenia; 36 are open to participants now.
Browse Febrile Neutropenia studies →1 of the 16 studies in Febrile Neutropenia with a site in France is open now. Recruiting first, the newest first:
Versailles Hospital · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 19 Febrile Neutropenia studies recruiting now, 11 (58%) set no upper age limit and 8 (42%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.
This study: 1 Year to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,900 is above the median of 131 across 46 observational studies indexed under Febrile Neutropenia.
Median enrollment 484 across the 6 interventional studies, 122 across the 10 observational. Of the 14 that completed or were terminated, 2 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 16 have an industry lead sponsor. The 10 most frequent:
University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.
University Hospital, Lille has 2 studies filed under Febrile Neutropenia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Febrile Neutropenia with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Evaluate the reproducibility and validate a posteriori a new rule of clinical decision on a multi-center population of children with a post-chemotherapy febrile neutropenia
Patient with hematology or cancer who consults for febrile neutropenia post-chemotherapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Blood culture
Presence or not of bacteriemia
Time frame: On average between 5 days and 1 month
Positive bacterial culture from a normally sterile site
Presence or not of bacterial infection
Time frame: on average between 5 days and 1 month
microbiological culture
Presence or not of focal infection at high risk of dissemination was defined as any local infection with or without microbiological documentation into a normally sterile site, with significant risk of loco-regional or systemic spread
Time frame: On average between 5 days and 1 month
Fungal culture
Presence or not of fungal infection is referred to a proven, probable, or possible fungal infection as defined by the IFICG ot the EORTC
Time frame: On average between 5 days and 1 month
Plan to share: No
The record gives a start of May 2012, a primary completion of May 2017 and a completion of May 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.